Power Law company profile

Shanghai Henlius Biotech

Biotech & Life Sciences · Huangpu, China · Founded 2009 · IPO 2019 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$5.40B

Market cap · Apr/2026

Revenue

$917M

Latest reported FY

Investors

6 investors on Shanghai Henlius Biotech's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series B+ 6 investors entered at this stage

ShenZhen GTJA Investment Group

CICC

The Cathay Funds

Korea Investment Partners

Loyal Valley Capital

Founder H Fund

Global footprint

Where Shanghai Henlius Biotech has talent and traffic

Web traffic by country

44K monthly visits
across markets

🇩🇰 Denmark52%

🇯🇵 Japan12.5%

🇺🇸 United States6.8%

🏳️ Korea6.6%

🏳️ Republic of3.9%

Top 5 markets shown

Patent intelligence

$49M patent portfolio · 148 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with topic prominence vs same-sector peers.

Estimated portfolio value

$49M

0.90% of market cap · 6.7× smaller than top peer Genmab ($328M)

148 active patent families

Where Shanghai Henlius Biotech innovates Antiendomysial antibodiesMolecular biologyBiochemistryImmunologyAnti antibody

Tech-focus vs peers

Where Shanghai Henlius Biotech concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Shanghai Henlius Biotech and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Shanghai Henlius Biotech on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo